MASH & Liver Disease
Explore peptide research and guides on mash & liver disease.
MASH & Liver Disease
MASH: Peptide Solutions for Liver Disease
MASH (formerly NASH) affects 5-14% of adults globally. Semaglutide, tirzepatide, and survodutide show resolution rates of 44-74% in clinical trials.
MASH & Liver DiseaseSemaglutide for Liver Fat: What the MASH Data Shows
Semaglutide resolved MASH in 63% of patients in the ESSENCE phase 3 trial and earned FDA approval. Review of 18 studies on GLP-1 therapy for liver fat.